1101

Chimeric Announces Launch of New Phase 1B Glioblastoma Clinical Trial

Retrieved on: 
Monday, June 5, 2023
GBM, SCRI, Clinical trial, ASX, Part, Glioblastoma, City, Patient, CHM, 1101, ST, IND, Safety, Sarah Cannon Research Institute, Pharmaceutical industry, Vaccine

“We are very excited to be activating the first site in our CHM 1101 Phase 1B clinical trial as it marks a new chapter in the development of CHM 1101,” said Jennifer Chow, CEO and Managing Director of Chimeric Therapeutics.

Key Points: 
  • “We are very excited to be activating the first site in our CHM 1101 Phase 1B clinical trial as it marks a new chapter in the development of CHM 1101,” said Jennifer Chow, CEO and Managing Director of Chimeric Therapeutics.
  • “This multi-center trial will enable us to more rapidly advance the development of CHM 1101 with recruitment across multiple clinical trial sites and also prepare us to accelerate the next phase of development if supported by the clinical results.”
    This Phase 1B trial, being conducted under a US IND, is a two-part clinical trial designed to determine a recommended Phase 2 dose and administration schedule.
  • “We’re very pleased to be building upon the City of Hope investigator-initiated trial and advancing CHM 1101 to a multi-center clinical trial.
  • CHM 1101 demonstrated safety with ~70% disease stability in the initial two dose cohorts in the City of Hope Phase 1A investigator-initiated clinical trial.

American Real Estate Partners Acquires Office to Apartment Conversion Investment in the Heart of Old Town, Alexandria

Retrieved on: 
Monday, September 12, 2022
Other Construction & Property, Residential Building & Real Estate, Commercial Building & Real Estate, Construction & Property, Icahn Enterprises, Senior management, 1101, LinkedIn, Acquisition, AREP, King Street, Investment, Paris Croissant, CEO, Walking, William King (St Mary Hall), Work, Heart, Greystar Real Estate Partners, Paris, Newsroom, Multimedia, Amazon, Commercial property, Hotel, Washington metropolitan area

American Real Estate Partners (AREP), today announced the companys acquisition of 1101 King Street in the heart of Old Town, Alexandria.

Key Points: 
  • American Real Estate Partners (AREP), today announced the companys acquisition of 1101 King Street in the heart of Old Town, Alexandria.
  • This is AREPs fifth investment through its Strategic Opportunity Fund III (Fund III) which is now 60% deployed.
  • This latest acquisition is part of AREPs broader strategic investment focus targeting industrial, data center, residential, and office assets across East Coast urban & urbanized suburban markets.
  • All office leases were restructured to allow for a deconversion of the office condominium and redevelopment into a mixed-use property.

Proactive news headlines including Kaiser Reef, Okapi Resources, Eastern Metals and Critical Resources

Retrieved on: 
Friday, June 10, 2022
STK, Sunburst, Calendar, US, GDC, OTC, Mannville Group, Proactivity, CRR, A1 Mine Settlement, AIM, SVM, CHM, Metal, 1101, GLOBE, EMS, Gibson, Sempra Metals Ltd v IRC, Glauconite, Gold, Millrose Games, Sammons, Lyon, ASX, BNL, Oil, Mining, Uranium

Click here

Key Points: 
  • Click here
    Okapi Resources Ltd (ASX:OKR) is about to kick off a summer field exploration program across its exploration projects in the world-renowned Athabasca Region.
  • Click here
    Critical Resources Ltd (ASX:CRR) has intersected further high-grade intersections of base and previous metals in sulphide mineralisation during diamond drilling at the Gibson prospect of the Halls Peak Project in New South Wales.
  • Click here
    Emmerson Resources Ltd (ASX:ERM) has been awarded three co-funding grants through the Northern Territory Geological Surveys (NTGS) Geophysics and Drilling Collaborations (GDC) program.
  • For more information on how Proactive can help you make a difference, email us at [email protected]

Chimeric enters strategic manufacturing partnership with WuXi Advanced Therapies

Retrieved on: 
Tuesday, April 12, 2022
CGMP, CDH17, Glioblastoma, Good manufacturing practice, 1101, CHM, Lymphatic system, Clinical trial, CAR, Program, Cancer, CEO, University, Gastrointestinal cancer, ASX, GLOBE, Acceleration, Wuxi, WuXi AppTec, NK, GMP, Patient, Partnership, City, Pharmaceutical industry, Medical imaging, Vaccine, Fine chemical, Chimera

MELBOURNE, Australia, April 11, 2022 (GLOBE NEWSWIRE) -- Chimeric Therapeutics (ASX:CHM, Chimeric) a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that it has entered into a strategic manufacturing partnership with WuXi ATU, a global contract testing and manufacturing organization (CTDMO).

Key Points: 
  • MELBOURNE, Australia, April 11, 2022 (GLOBE NEWSWIRE) -- Chimeric Therapeutics (ASX:CHM, Chimeric) a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that it has entered into a strategic manufacturing partnership with WuXi ATU, a global contract testing and manufacturing organization (CTDMO).
  • We are very excited to enter into this partnership with WuXi ATU, said Jennifer Chow, CEO of Chimeric Therapeutics.
  • Dr David Chang, CEO of WuXi Advanced Therapies, added, Were delighted to partner with Chimeric Therapeutics to accelerate the development of two of their autologous CAR T cell programs.
  • WuXi Advanced Therapies, a global Contract Testing Development and Manufacturing Organisation (CTDMO), is the advanced therapies business unit of WuXi AppTec and offers integrated platforms to transform the discovery, development, testing, manufacturing, and commercialization of cell and gene therapies for customers worldwide.

Chimeric Transforms Portfolio With a Clinically Validated, Off the Shelf, Natural Killer (NK) Cell Platform

Retrieved on: 
Wednesday, December 1, 2021
Patient, Research, CAR, Basic research, Safety, Cell, Technology, Merck, ASX, Partnership, MD, Cancer, Clinical trial, 1101, Doctor of Philosophy, University, NK, Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center, City, Glioblastoma, Janssen, CDH17, GLOBE, Phases of clinical research, Case, Associate, Case Western Reserve University, Therapy, CWRU, Lymphatic system, Vaccine, Pharmaceutical industry, Medical imaging, Medical device, Fine chemical

Natural killer (NK) cells have innate safety features and the natural ability to target and destroy cancer cells through both indirect and direct mechanisms.

Key Points: 
  • Natural killer (NK) cells have innate safety features and the natural ability to target and destroy cancer cells through both indirect and direct mechanisms.
  • The challenge with natural killer (NK) cells is that they are not naturally abundant or active enough to overcome cancer.
  • Preclinical data on the CORE-NK platform was published in the prestigious family of Nature publications in 2019.
  • The phase 1 clinical trial of the CORE-NK platform was completed in June 2021 with clinical data expected in 2022.